Head-To-Head Review: Ionis Pharmaceuticals (NASDAQ:IONS) & Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT)

Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT) and Ionis Pharmaceuticals (NASDAQ:IONS) are both mid-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, dividends, risk, profitability, analyst recommendations, earnings and institutional ownership.

Analyst Recommendations

This is a summary of recent recommendations for Lakefront Biotherapeutics American Depositary Shares and Ionis Pharmaceuticals, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lakefront Biotherapeutics American Depositary Shares	0	5	3	0	2.38
Ionis Pharmaceuticals	1	3	19	0	2.78

Lakefront Biotherapeutics American Depositary Shares presently has a consensus target price of $35.50, suggesting a potential upside of 6.13%. Ionis Pharmaceuticals has a consensus target price of $89.48, suggesting a potential upside of 126.98%. Given Ionis Pharmaceuticals’ stronger consensus rating and higher probable upside, analysts clearly believe Ionis Pharmaceuticals is more favorable than Lakefront Biotherapeutics American Depositary Shares.

Institutional & Insider Ownership

32.5% of Lakefront Biotherapeutics American Depositary Shares shares are owned by institutional investors. Comparatively, 93.9% of Ionis Pharmaceuticals shares are owned by institutional investors. 2.9% of Lakefront Biotherapeutics American Depositary Shares shares are owned by insiders. Comparatively, 1.8% of Ionis Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Profitability

This table compares Lakefront Biotherapeutics American Depositary Shares and Ionis Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Lakefront Biotherapeutics American Depositary Shares	N/A	N/A	N/A
Ionis Pharmaceuticals	-64.76%	-111.08%	-17.41%

Risk and Volatility

Lakefront Biotherapeutics American Depositary Shares has a beta of 0.22, indicating that its stock price is 78% less volatile than the S&P 500. Comparatively, Ionis Pharmaceuticals has a beta of 0.43, indicating that its stock price is 57% less volatile than the S&P 500.

Valuation & Earnings

This table compares Lakefront Biotherapeutics American Depositary Shares and Ionis Pharmaceuticals”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lakefront Biotherapeutics American Depositary Shares	$990.57 million	2.23	$363.05 million	($1.41)	-23.72
Ionis Pharmaceuticals	$944.00 million	6.94	-$381.39 million	($3.46)	-11.39

Lakefront Biotherapeutics American Depositary Shares has higher revenue and earnings than Ionis Pharmaceuticals. Lakefront Biotherapeutics American Depositary Shares is trading at a lower price-to-earnings ratio than Ionis Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

About Lakefront Biotherapeutics American Depositary Shares

Galapagos NV, an integrated biopharmaceutical company, engages in the discovery, development, and commercialization of various medicines for high unmet medical need. Its pipeline products include filgotinib, a JAK1 inhibitor that is in various phases of clinical trials for the treatment of rheumatoid arthritis, Crohn’s disease, ulcerative colitis, small bowel CD, fistulizing CD, ankylosing spondylitis, psoriatic arthritis, and uveitis. The company’s pipeline products also comprise GLPG1972 that has completed Phase 2b trial for treating osteoarthritis; Toledo molecules, including GLPG3970, GLPG4399, and GLPG4876 for inflammation; and GLPG4716 and Ziritaxestat to treat idiopathic pulmonary fibrosis. In addition, its other pipeline products include GLPG2737, a cystic fibrosis transmembrane conductance regulator that is in Phase 2 clinical trials to treat patients with autosomal dominant polycystic kidney disease; and GLPG0555, a JAK1 inhibitor, which is in Phase 1b for treatment of patients with osteoarthritis. The company has collaboration agreements with Gilead Sciences, Inc.; AbbVie S.à r.l.; and Novartis Pharma AG. Galapagos NV was incorporated in 1999 and is headquartered in Mechelen, Belgium.

About Ionis Pharmaceuticals

Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy. It also develops medicines for various indications that are in phase 3 study, including Eplontersen as a monthly self-administered subcutaneous injection to treat all types of ATTR; Olezarsen for patients with FCS and severe hypertriglyceridemia (SHTG); Donidalorsen for patients with hereditary angioedema; ION363 for patients with amyotrophic lateral sclerosis; Tofersen to inhibit the production of superoxide dismutase 1; Pelacarsen for patients with established cardiovascular disease and elevated lipoprotein(a); and Bepirovirsen to inhibit the production of viral proteins associated with hepatitis B virus. In addition, the company develops IONIS-FB-LRx to inhibit the production of complement factor B and the alternative complement pathway; and ION224 to reduce the production of diacylglycerol acyltransferase 2. It has a strategic collaboration with Biogen for the treatment of neurological disorders; and collaboration and license agreement with Metagenomi, Inc, AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis, Roche, Swedish Orphan Biovitrum AB, and PTC Therapeutics. The company was incorporated in 1989 and is based in Carlsbad, California.